Cre Recombinase, TAT-Cre (Tat-NLS-Cre, HTNC, HTNCre), Lyophilized

• $100 First Order Discount: Use code CreDiscount for 1 mg purchases
• $150 Competitor Switch Discount: Email crm@excellgen.com for code

TAT-Cre Recombinase is an enhanced, cell-permeable version of the bacteriophage P1 Cre recombinase engineered for high-efficiency genomic modifications.

Key Features:

• Mechanism: Catalyzes site-specific recombination between loxP sites (34bp sequence with 13bp inverted repeats)
• Fusion Tags:
  • N-terminal 6×His tag for purification
  • TAT peptide (GRKKRRQRRRPPAGTSVSL) for cell penetration
  • NLS sequence (PKKKRKV) for nuclear localization
• Efficiency: 60-90% transduction in reporter cells (1μM, 1-2h)
• Enhancement: 100μM chloroquine boosts transduction

Applications:

• Conditional gene knockout/knockin in floxed systems
• Tissue-specific or drug-inducible (Cre-ER^T2) gene manipulation
• Rapid allele conversion in embryos and cultured cells

• Molecular Weight: 43 kDa
• Purity: >98% (SDS-PAGE/HPLC)
• Endotoxin: <0.1 EU/μg
• Activity: 80-100% recombination in HEK293T reporter cells at 1μM
• Unit Definition: 100U = amount (μg) needed for 50% GFP expression in HEK293T reporter cells

Figure 1: Recombination timeline (0: pre-treatment; 1-5: days post-transduction)

Figure 2: Stability comparison of liquid vs lyophilized TAT-Cre

• -80°C: 5 years
• -20°C: 2 years
• 4°C: 1 year
• Ambient: 6 months (lyophilized)

1. Rapid allele conversion in embryos (Transgenic Res. 2014) doi:10.1007/s11248-013-9764-x
2. Defective glucose metabolism in PKD (Nat Med. 2013) doi:10.1038/nm.3092
3. Kinase-independent TAK1/TAB1 regulation (MCB 2013) doi:10.1128/MCB.06407-11
4. IL-17 mediated epithelial changes (J Immunol. 2013) doi:10.4049/jimmunol.1301360
5. Enhancer rearrangement in leukemia (Cell 2014) doi:10.1016/j.cell.2014.02.019

Additional references available upon request